Cryoport Inc (CYRX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Cryoport inc   (NASDAQ: CYRX)


Cryoport Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Cryoport Inc's ROI in the second quarter of 2026?
Cryoport Inc recorded a cumulative net loss of $-43 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -6.33%.

Within the Healthcare sector 225 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 713 to 726.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 3.15 % 1.92 % -4.34 % -14.75 % -25.23 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 727 539 732 744 744
Return On Investment (TTM) -6.33 % 10.69 % 10.16 % 9.46 % 10.99 %
CYRX's Overall Ranking # 726 # 713 # 552 # 864 # 596
Seq. Investment Change TTM -0.61 % -3.06 % 3.06 % 3.89 % -1.8 %
Seq. Net Income Change TTM - 1.99 % 10.78 % -10.61 % -
Net Income (TTM) in Millions -43 74 72 65 73




Return On Investment CYRX's Ranking
Within: No.
Industry # 80
Sector # 226
Overall # 726

Return On Investment Statistics
High Average Low
11.23 %
-140.69 %
-2327.47 %
(Mar 31 2026)   (Sep 30 2013)







Financial Statements
Cryoport Inc's II. Quarter Investments $ 727 Millions CYRX's Balance sheet
Cryoport Inc's II. Quarter Income $ -8 Millions Quarterly CYRX's Income Statement
CYRX's Income by Division See CYRX's Income by Division


CYRX Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2020
Total Investments in Millions 546 639 912 998 1,070
Y / Y Investment Growth -14.55 % -29.95 % -8.59 % -6.77 % 720.73 %
Net Income in Millions 70 -123 -108 -45 -284
Y / Y Net Income Growth - - - - -
Annual Return On Investment 12.88 % -19.21 % -11.8 % -4.54 % -26.51 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 12.88 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CYRX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CYRX's Competitors
Subscribers only: Roi for Cryoport Inc's Suppliers
Subscribers only: Return On Investment for CYRX's Customers

Other Ratios
CYRX's Roa CYRX's Inventory Turnover Ratio CYRX's Growth Rates CYRX's Dividend Statistics
CYRX's Profitability Ratios CYRX's Asset Turnover Ratio CYRX's Dividend Growth
CYRX's Roe CYRX's Valuation Ratios CYRX's Financial Strength Ratios CYRX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI


Date modified: 2026-09-12T06:10:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.